

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/537,710	03/30/2000	Anders Dahlqvist	3377/99-Util	9098	
26474	7590 08/09/2006		EXAMINER		
NOVAK DRUCE DELUCA & QUIGG, LLP			ROBINSON, HOPE A		
1300 EYE STREET NW SUITE 400 EAST TOWER			ART UNIT	PAPER NUMBER	
WASHINGTO	ON, DC 20005		1656		
			DATE MAILED: 08/09/200	6	

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

CONTROL NO.	FILING DATE	PATENT IN REEXAMINATION		ATTORNEY DOCKET	NO.
09/537 710					
,				EXAMINER	
			ART UNIT	PAPER	

20060803

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The amendment filed on May 23, 2006 does not comply with the sequence rules. The Office Action mailed on December 1, 2005 indicated that the present application is non-compliant with the sequence rules because the present computer readable form and sequence listing has 21 sequences, however, in an amendment filed on July 27, 2004 the amendment made to the specificatin lists SEQ ID NOS:24-27, for example. The response filed on May 23, 2006 refers to filing 21 sequences following a correction, however, did not amend the specification to remove entry of sequences, identified as SEQ ID NOS:24-27, for example. Therefore, as these sequences are a part of the instant specification, the application does not comply with the sequence rules.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR1.821 through 1.825; applicant's attention is directed to the final rule making notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). To be in compliance, applicant is required to either amend the specification to delete references to sequences beyond the 21 in the computer readable form or provide a new paper copy and computer readable form with the sequences beyond SEQ ID NO:21, along with the required statement. Applicant is reminded to identify all amino acid sequences of at least 4 L-amino acids and at least 10 nucleotides by a sequence identifier, i.e., "SEQ ID NO:" (see 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.821(b) or 1.825(d) and the attached Notice to Comply with the sequence rules).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hope A. Robinson whose telephone number is 571-272-0957. The examiner can normally be reached on Monday-Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr, can be reached at (571) 272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

PROPEROBINSON BATENT EXAMINER

Hope Robinson, MS Patent Examiner 412) 04

PTO-90C (Rev.04-03)